$20.05
0.45% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Prothena Corp. Plc Stock price

$20.05
-1.32 6.18% 1M
-5.11 20.31% 6M
-16.29 44.83% YTD
-27.40 57.75% 1Y
-57.34 74.09% 3Y
+12.25 157.05% 5Y
-2.73 11.98% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.09 0.45%
ISIN
IE00B91XRN20
Symbol
PRTA
Sector
Industry

Key metrics

Market capitalization $1.08b
Enterprise Value $531.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.44
P/S ratio (TTM) P/S ratio 4.99
P/B ratio (TTM) P/B ratio 1.86
Revenue growth (TTM) Revenue growth 276.98%
Revenue (TTM) Revenue $217.25m
EBIT (operating result TTM) EBIT $-91.36m
Free Cash Flow (TTM) Free Cash Flow $-99.23m
Cash position $564.12m
EPS (TTM) EPS $-1.01
P/E forward negative
P/S forward 7.57
EV/Sales forward 3.71
Short interest 16.40%
Show more

Is Prothena Corp. Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Prothena Corp. Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Prothena Corp. Plc forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Prothena Corp. Plc forecast:

Buy
78%
Hold
22%

Financial data from Prothena Corp. Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
217 217
277% 277%
100%
- Direct Costs 18 18
-
8%
199 199
-
92%
- Selling and Administrative Expenses 30 30
23% 23%
14%
- Research and Development Expense 241 241
36% 36%
111%
-73 -73
56% 56%
-34%
- Depreciation and Amortization 18 18
163% 163%
8%
EBIT (Operating Income) EBIT -91 -91
47% 47%
-42%
Net Profit -51 -51
64% 64%
-23%

In millions USD.

Don't miss a Thing! We will send you all news about Prothena Corp. Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Prothena Corp. Plc Stock News

Neutral
Business Wire
about 4 hours ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that Chad Swanson, Ph.D., has been appointed Chief Development Officer.
Neutral
Business Wire
29 days ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in September 2024.
Neutral
Business Wire
about 2 months ago
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced that it will report its second quarter and first six months of 2024 financial results on Thursday, August 8, 2024.
More Prothena Corp. Plc News

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Gene Kinney
Employees 173
Founded 1969
Website www.prothena.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today